Collplant issues letter to shareholders

Rehovot, israel , jan. 24, 2023 /prnewswire/ -- collplant (nasdaq: clgn), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, is pleased to issue the following letter from its chief executive officer, yehiel tal, to its shareholders.     view as pdf dear shareholders, as we look toward a promising and exciting year ahead, i am proud to reflect on collplant's achievements throughout 2022.
CLGN Ratings Summary
CLGN Quant Ranking